AngioLab Profile
A biotechnology company specialized in angiogenesis
Established in 1999 and awarded numerous Korean government-research grants
Possesses more than 50 international and domestic patents
Developing products based on angiogenesis inhibitors
Field of Business
AL101-AOB (Abdominal obesity)
AL101-AMD (Age-related macular degeneration)
AL101-MASH (Metabolic dysfunction-associated steatohepatitis)
AL102-PDT (Periodontitis)
AL101-OME (Otitis media with effusion)
AL101-ROSA (Rosacea)
AL101-PSO (Psoriasis)
AL201-AB (Antibody)
Ob-X (Health functional food with proven claims of visceral fat reduction)
Vision
